c-Abl kinase is activated in PD substantia nigra and phosphorylates parkin at Tyr143, inhibiting its E3 ligase activity and impairing ubiquitination of α-synuclein substrates. Selective c-Abl inhibitors (K0706) block parkin inactivation, enhancing degradation of pathological substrates. Phase 2 nilotinib trial showed safety but modest efficacy, suggesting that next-generation selective inhibitors may be needed for meaningful benefit.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["c-Abl / ABL1 Kinase Activation"]
B["Mitochondrial Apoptosis"]
C["Alpha-Synuclein Phosphorylation"]
D["Parkinson Pathology"]
E["Therapeutic Inhibition"]
F["Synuclein Clearance Restoration"]
G["Neuroprotection Disease Modification"]
A --> B
A --> C
B --> D
C --> D
E --> A
E --> F
F --> G
D --> G
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Median TPM across 13 brain regions for ABL1/c-Abl from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMIDValidation: 0%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
1
MECH 4CLIN 1GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
c-Abl activity elevated in PD substantia nigra and…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
The hypothesis rests on a coherent, genetically informed mechanism connecting TREM2 function to microglial-mediated amyloid homeostasis. TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a surface receptor enriched in microglia and macrophages that signals through a structured cascade: SYK kinase → PLCγ2 → CARD9 → NF-κB/calcineurin-NFAT signaling. This pathway modulates microglial survival, proliferation, chemotaxis toward plaques, and phagocytic c
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
The Round 1 critique correctly identified the genetic foundation and mechanistic coherence of the TREM2-amyloid hypothesis. I will extend this analysis with specific attention to pharmacological uncertainties, causal chain weaknesses, and experimental design limitations that remain unresolved.
Critical Weaknesses and Evidence Gaps
1. Biphasic Dose-Response Pharmacology: A Fundamental Concern
The biphasic dose-response observed with TREM2 agonist
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Expert Assessment: TREM2 Agonism for Alzheimer's Disease
Executive Summary
The TREM2 hypothesis remains one of the most genetically validated targets in Alzheimer's disease drug development, but faces significant translational hurdles that temper enthusiasm despite the 0.82 confidence score. The genetic architecture (R47H as strong loss-of-function risk variant) provides compelling justification for agonist approaches, yet pharmacology complexity and clinical translation gaps create meaningful uncertainty.
Target Druggability Assessment
Classification
**TREM2 is a "drugg
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Synthesis: TREM2 Microglial Activation for Amyloid Clearance in Alzheimer's Disease
Dimension Scores
| Dimension | Score | Rationale | |-----------|-------|-----------| | Mechanistic Plausibility | 0.88 | R47H variant provides strong loss-of-function evidence; SYK/PLCγ2/CARD9 cascade is well-defined; connects microglial dysfunction to amyloid pathology | | Evidence Strength | 0.68 | Human genetics is compelling, but preclinical-to-clinical translation remains incomplete; biphasic pharmacology complicates interpretation; model validity questions persist | | Novelty | 0.70 |
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
💬 Discussion
Loading comments...
No DepMap CRISPR Chronos data found for ABL1/c-Abl.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
IF A53T SNCA transgenic mice (Line 61) receive chronic oral K0706 (30mg/kg/day) for 8 weeks beginning at 12 months of age, THEN markers of autophagic flux (LC3-II/LC3-I ratio, p62 degradation rate) will increase by ≥50% in substantia nigra pars compacta tissue and striatal α-synuclein aggregate burden will decrease by ≥40% compared to vehicle-treated age-matched controls.
pendingconf: 0.60
Expected outcome: ≥50% increase in LC3-II/LC3-I ratio; ≥40% reduction in α-synuclein pSer129 immunoreactive aggregates in nigrostriatal tissue
Falsified by: No increase in autophagic flux markers (LC3-II/LC3-I ratio change <20%) AND no reduction in α-synuclein aggregate load (<15% change) in K0706-treated mice compared to vehicle controls, despite adequate brain penetration (brain K0706 concentration ≥1μM)
Method: Randomized controlled study in male A53T SNCA transgenic mice (n=12/group) treated with K0706 or vehicle from 12-14 months of age, with behavioral testing (rotarod, grip strength) biweekly, followed by biochemical (Western blot for LC3, p62, parkin Tyr143 phosphorylation) and immunohistochemical (pSer129 α-synuclein) analysis of nigrostriatal tissue
IF patients with idiopathic Parkinson's disease receive orally administered selective c-Abl inhibitor (K0706 at doses achieving >80% target engagement, e.g., 300mg daily) for 6 months, THEN cerebrospinal fluid α-synuclein concentrations will decrease by ≥25% from baseline and motor disability scores (MDS-UPDRS Part III) will improve by ≥5 points compared to placebo-treated controls.
pendingconf: 0.55
Expected outcome: ≥25% reduction in CSF α-synuclein concentration; ≥5-point improvement in MDS-UPDRS Part III score
Falsified by: No statistically significant reduction in CSF α-synuclein (<10% change) AND no improvement in motor scores (≤2-point change) in the treatment arm compared to placebo, despite confirmed target engagement (≥80% ABL1 inhibition in peripheral blood mononuclear cells)
Method: Phase 2 randomized, double-blind, placebo-controlled trial (n=120) in idiopathic PD patients (Hoehn-Yahr stage 2-3) with 6-month intervention, serial CSF sampling at baseline/month 3/month 6, and MDS-UPDRS assessments at baseline/month 2/month 4/month 6
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
ABL1 — Search for structure
Click to search RCSB PDB